McCarthy, J. S., Yalkinoglu, Ö., Odedra, A., Webster, R., Oeuvray, C., Tappert, A., Bezuidenhout, D., Giddins, M. J., Dhingra, S. K., Fidock, D. A., Marquart, L., Webb, L., Yin, X., Khandelwal, A., & Bagchus, W. M. (2021). Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. The Lancet Infectious Diseases, 21(12), 1713–1724. https://doi.org/10.1016/s1473-3099(21)00252-8